The Christie Hospital

Greater Manchester M20 4BX

1 studies enrolling now · 9 studies all time

What they study most

Acute Myeloid Leukemia, B-cell Malignancies, Chronic Lymphocytic Leukemia, Esophageal Squamous Cell Carcinoma (ESCC), Hepatocellular Carcinoma (HCC), MZL, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma

Studies at this site

• A Study of BGB-11417 in Participants With Myeloid Malignancies — Recruiting now
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL — Running, not enrolling
• Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies — Running, not enrolling
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed
• Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma — Running, not enrolling
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma — Completed
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed